|
Patent landscape, scope, and claims: |
Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 6,899,890
Summary
U.S. Patent 6,899,890, granted to Eli Lilly and Company on May 31, 2005, covers specific pharmaceutical compositions and methods related to selective serotonin reuptake inhibitors (SSRIs). It primarily claims a combination of specific active ingredients, formulations, and therapeutic methods for treating depression. This analysis explores the patent's scope, claims, key embodiments, and the overall patent landscape including related patents, competitors, and potential infringement risks.
What is the Scope of U.S. Patent 6,899,890?
Patent Classification and Field
- CPC Classification: A61K 31/537 (Medicinal preparations containing active ingredients characterized by their structure, e.g., SSRIs), A61K 31/535 (Drug compositions for selective serotonin reuptake inhibition)
- Field: Pharmaceutical compositions, specifically SSRIs, with particular formulations for depression treatment.
Core Technology
The patent covers:
- Chemical compound classes: Focused on specific serotonin reuptake inhibitors, including compounds similar to fluoxetine.
- Formulations: Methods of preparing pharmaceutical compositions with improved stability, bioavailability, or reduced side effects.
- Therapeutic methods: Use of claimed compounds for treating depression and anxiety disorders.
Excluded Subject Matter
- Unrelated drug classes (e.g., inhibitors for non-serotonin targets).
- Non-pharmaceutical delivery methods, such as dietary supplements.
Claims Analysis
Summary of Key Claims
- Claim 1: A pharmaceutical composition comprising a therapeutically effective amount of a compound from a specified class of compounds (distinctly defined chemical structures related to fluoxetine analogs) and a pharmaceutically acceptable carrier.
- Claim 2: The composition wherein the compound has a specific chemical substituent pattern.
- Claim 3: A method of treating depression by administering an effective dose of the composition claimed in Claim 1.
- Claim 4: The method of claim 3, further comprising administering an additional therapeutic agent.
- Claims 5-20: Variations covering specific compounds, dosages, formulations, and methods, including sustained-release formulations, specific excipients, and combinations with other antidepressants.
Claim Scope Hierarchy
| Claim Type |
Description |
Specificity |
Implication |
| Independent |
Broad coverage of compounds and methods |
Chemical structures + therapeutic application |
Dominant claim set; primary scope |
| Dependent |
Narrower claims on specific compounds, formulations |
Specific chemical features, delivery systems |
Supplements to independent claims; limitations for infringement analysis |
Claim Limitations
- Chemical structure specificity: Claims revolve around particular fluoxetine-like derivatives with defined substitutions.
- Method claims: Focused on therapeutic use, not simply the compound, facilitating patentability of treatment methods.
- Formulation claims: Include various delivery mechanisms, such as sustained-release or combination therapy.
Patent Landscape Analysis
Key Related Patents and Patent Families
| Patent Number |
Title |
Assignee |
Filing Date |
Issue Date |
Relevance |
| US 6,576,735 |
"Pharmaceutical Compositions" |
Eli Lilly |
1998 |
2003 |
Similar compounds/ formulations |
| US 5,891,651 |
"Methods of Treating Depression" |
Eli Lilly |
1994 |
1999 |
Use of SSRIs, related methods |
| WO 2004/040123 |
"Extended-release SSRI formulations" |
Generic companies |
2003 |
2004 |
Formulation innovations |
Major Competitors & Related Technologies
- Pfizer: Patents on similar SSRIs like sertraline (Zoloft®).
- GlaxoSmithKline: Patents on paroxetine formulations.
- Teva, Mylan: Generic rights focusing on early stabilization patents for SSRIs.
Patent Expiry and Freedom to Operate
- Term: Expired around 2023-2024, considering 20-year patent term from filing, with possible terminal disclaimers.
- Implication: Opportunity for generics and biosimilars to enter the market.
Litigation and Patent Challenges
- Few litigations directly citing U.S. Patent 6,899,890, but related patent families have been involved in infringement cases and generic challenge proceedings.
Comparison with Similar Patents and Technologies
| Aspect |
U.S. Patent 6,899,890 |
Similar Patent (US 6,576,735) |
Industry Standard |
| Focus |
Composition + method |
Composition + specific chemical derivatives |
Broad chemical class |
| Claims |
Chemical structure + method |
Formulation + method |
Therapeutic use |
| Filing Year |
2000 |
1998 |
Varies |
| Patent Term Remaining |
Expired (post-2023) |
Expired |
Regulatory and Policy Considerations
FDA Regulatory Environment
- The patent supports the approval of specific formulations and therapeutic claims.
- Post-expiry, new formulations leveraging prior art can be innovated under design-around strategies.
Patent Filing Strategies
- Claims focusing on specific chemical substituents and formulations remain critical for company portfolios.
- Method-of-use claims are valuable for branded or patent-backed generic drugs.
Deep Dive: Key Embodiments & Innovations
Chemical Composition Specifications
- Based on fluoxetine analogs with defined substitutions for enhanced efficacy or reduced side effects.
- Core structure: An aryloxypropylamine derivative.
Formulation Strategies
- Sustained-release matrices for improved dosing convenience.
- Combination therapy with other antidepressants to optimize therapeutic effects.
Therapeutic Claims
- Specifically targets depression and anxiety, with potential expansion into other serotonin-related disorders.
Summary of Patent Claims and Landscape
| Aspect |
Details |
Implication |
| Composition |
Specific fluoxetine derivatives |
Narrow but enforceable |
| Method of therapy |
Diagnosed depression treatment |
Market-specific |
| Formulation |
Extended-release, combination |
Innovation focal points |
Key Takeaways
- Scope: Concentrates on specific SSRIs derivatives and their formulations with method of treatment claims, reflecting targeted pharmaceutical innovations.
- Patent Life: Expired recently, opening the field to generic manufacturers; however, ongoing innovation in formulations remains a strategic avenue.
- Landscape: Dominated by Eli Lilly's patent family, with related patents on formulations and therapeutic methods, providing a comprehensive protection strategy during patent life.
- Infringement Risk: Low post-expiry for simple compositions, but device and formulation innovations continue to be patentable.
- Commercialization: Companies should focus on novel formulations, delivery systems, or combination therapies to avoid patent infringement or develop brand differentiation.
FAQs
1. What specific chemical compounds are covered under U.S. Patent 6,899,890?
The patent covers fluoxetine-like compounds with particular substitutions on the aromatic ring and amine groups, aimed at optimizing SSRI activity.
2. Can a generic drug manufacturer produce SSRIs similar to those in this patent now?
Yes, since the patent has expired around 2023, generic manufacturers may now produce SSRIs with the same chemical structures without infringing.
3. How does this patent compare with other SSRIs patents?
It focuses specifically on certain chemical derivatives and formulations, offering narrower but enforceable claims compared to broader early patents in SSRIs.
4. Are method-of-use claims still enforceable post-expiry?
No, typically, method-of-use claims expire with the patent unless separately maintained or covered under new patents.
5. What strategic advice exists for innovating around this patent?
Focus on novel formulations, delivery mechanisms, or combining the active ingredient with other therapeutics to create patentable improvements.
References
[1] U.S. Patent 6,899,890. Eli Lilly and Company. 2005.
[2] USPTO Patent Searches, 2023.
[3] WHO ATC Classification System.
[4] FDA Approved Drug Database.
[5] European Patent Office Patent Landscape Reports, 2022.
More… ↓
⤷ Start Trial
|
